CheckMate 9DW Expanded Analyses: Nivo/Ipi Versus Len/Sor as 1L Therapy for uHCC
By Christopher Lieu, MD - Last Updated: February 6, 2025Christopher Lieu, MD, of University of Colorado Medicine, reviews the CheckMate 9DW trial that was presented at ASCO GI 2025, which examined nivolumab plus ipilimumab against lenvatinib plus sorafenib in patients with advanced or unresectable hepatocellular carcinoma.
Advertisement
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care for this disease.
Post Tags:ASCO GI 2025: Focus on Liver Cancer
Advertisement
Related Posts
Dr. Maen Abdelrahim reflects on the multidisciplinary collaboration required to make transplant oncology a clinical reality.
GI Oncology Now spoke with experts about HCC, how its management is changing, and how advancements are reshaping the disease.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.